How Dymista® is used by patients

Dymista® is a dual-action treatment3 that is clinically proven to relieve the symptoms of moderate to severe allergic rhinitis.4 The two active ingredients (fluticasone propionate/azelastine hydrochloride), combined with the formulation,5 give Dymista® a rapid onset of action and symptom relief for your patients.6

A product that is easy to use, effective, and works quickly is important for maintaining adherence to therapy, and this in turn has a positive effect on clinical outcomes. Therefore, it is important that patients know the correct method for administering Dymista®.

Correct administration technique:5

1Shake the bottle gently for 5 seconds by tilting it upwards and downwards and then remove the protective cap.

2The first time the nasal spray is used, you must prime the pump:

  • Put one finger either side of the spray pump and place your thumb on the bottom of the bottle.
  • Press down and release the pump 6 times until a fine mist appears.
  • Now your pump is primed and ready to use.
  • If the nasal spray has not been used for more than 7 days, you will need to re-prime the pump once by pressing down and releasing the pump.

3Using the spray:

  • After blowing your nose, spray once into each nostril keeping the head tilted downward (see video).
  • The spray tip should be directed to the outside wall of the nose, using the right hand for the left nostril and the left hand for the right nostril.
  • Do not sniff; breathe in gently.
  • After use, wipe the spray tip and replace the protective cap.

Watch the video below for a tutorial:

HOW TO USE DYMISTA®

References

  • Scadding GK, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy 2017; 47(7): 856‑889.
  • Scottish Medicine Consortium (SMC). Available at https://www.scottishmedicines.org.uk/medicines-advice/azelastine-hydrochloride-plus-fluticasone-propionate-dymista-abbreviatedsubmission-92113/. Last accessed: November 2018.
  • Derendorf H, et al. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol. 2012; 74(1): 125-133.
  • Klimek L, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: Results from a noninterventional study. Allergy Asthma Proc. 2015; 36(1): 40-47.
  • Dymista® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9450. Last accessed: November 2018.
  • Bousquet J, et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. J Allergy Clin Immunol Pract. 2018; 6(5): 1726-1732.

The website you are trying to access is designed for healthcare professionals in the UK, the content is not designed for the general public.

Are you a UK healthcare professional?

YES
NO